07 rencontres biomédicale LIR Bart Staels

  • 753 views
Uploaded on

2ND INTERNATIONAL RESEARCH MEETING …

2ND INTERNATIONAL RESEARCH MEETING
4 JUNE 2010- HÔTEL DE MARIGNY PARIS

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads

Views

Total Views
753
On Slideshare
0
From Embeds
0
Number of Embeds
0

Actions

Shares
Downloads
0
Comments
0
Likes
0

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide
  • HD: i have replaced the title by the project title
  • HD: format changes to fit the screen; 05/11/2008: change title (add ‘hypothesis’)
  • HD: front change so that the ‘nuclear receptor’ fit into the circles + 05/11/2008: I have added the nature med reference

Transcript

  • 1.
  • 2. Bart Staels Diabetes: from risk factors to cardiovascular complications Université Lille Nord de France; INSERM U1011; Institut Pasteur de Lille; Lille, France The « European Genomics Institute of Diabetes » (EGID) project in Lille
  • 3. Obesity predisposes to diabetes and cardiovascular disease
  • 4. Nutrition Exercise Signal transduction pathways Transcription factors Genes Insulin resistance Inflammation Hyper- tension Lipid disorders
  • 5. Clock Sleep-wake cycles Body temperature Activation of intestinal system Endocrine systems Liver metabolism Renal activity Cardiovascular system (blood pressure, heart beat, …) Example 1: Circadian dysregulation and Metabolic disorders
  • 6. Clock outputs Physiological response / metabolic adaptation Metabolic signals Molecular pathways? (ex.Rev-erb  and ROR  ) Chronopharmacology
  • 7. Clock transcription factors link circadian oscillators to metabolic pathways Staels B . , Nature Medicine , 2006 Light Peripheral tissues Food availability (glucose) Hormones (insulin) SCN (hypothalamus) Clock Bmal1 Cry Per Rev-erb  ROR 
    • Rev-erb 
    • ROR 
    • PPARs,..
    Target genes Glucose metabolism (PEPCK), Bile acid metabolism (CYP7A1), Lipid metabolism (FAS),… ‘ Metabolic’ transcription factors NRE Nuclear receptor Nuclear receptor
  • 8. Normal state NR interactome A Cistrome A Regulon A Example 2: Molecular analysis of gene regulation in cardiometabolic diseases Pathological state Epigenetic events NR interactome B Regulon B Cistrome B
  • 9. Lean PPAR  interactome A Cistrome A Regulon A GO functional classification: 1) Extracellular signalling 2) Carboxylic acid metabolism 3) Oxido-reduction 4) Development 5) Subcellular transport Role of the proteasome in the response visceral WAT responsiveness to PPAR  Lefebvre et al. J.Clin.Invest. 2009 Hypoxia UCHL1, Proteasome Obese PPAR  interactome B Regulon B Cistrome B GO functional classification: 1) Monocarboxylic acid and lipid metabolism 2) Mitochondrion 3) Metabolic processes 4) Glucose and pyruvate metabolism 5) Citrate cycle
  • 10. European Consortia
      • DIABESITY ( 24 partners, integrated project )
      • HEPADIP (26 partners, integrated project)
      • IAP Stigo (20 partners)
      • X-TRA-NET (5 partners, specific target project)
      • TOBI (10 partners, Collaborative project)
      • OLNORME (4 partners, Era-Net involving Genfit)
      • EVGN (28 partners, Network)
      • COST BM0602 (Network)
  • 11. Diagnostic tools
    • Therapeutic compounds:
    • Innovating compounds / β cell mass restauration
    • Valorisation of research tools
    IT-DIAB (2008-2012)
        • National consortium
        • Industry (4) / academic teams (8)
        • Support A2I / OSEO
    Diabesity DIAGNOSTIC THERAPY MONITORING R & D UMR 8090 U 859 U1011
  • 12. European Genomics Institute of Diabetes : a model of industrie – academia partnership, towards tomorrow’s treatments Basic Research Clinical Research Translational Research Valorisation Platform Pharmaceutical industrie
  • 13. Who …………........ and why EGID?
    • Vamberghe &
    • P. Fontaine
    P. Froguel B. Staels F. Pattou
    • Create high-technology platforms dedicated
    • to diabetes research
    • 2) Develop translational and clinical research
    • activities
    • 3) Host new research teams
    • 4) Create and coordinate collaborative
    • projects (EU)
    • 5) Develop a valorisation platform to collaborate
    • with pharma industry